Ivonescimab Shows Statistically Significant Survival Benefit in Phase III HARMONi-2 Trial for NSCLC

An interim analysis of the Phase III HARMONi-2 study reveals that ivonescimab meets key secondary endpoints for overall survival, demonstrating clinically meaningful benefits compared to pembrolizumab in first-line PD-L1-positive non-small cell lung cancer patients.

2 Sept, 21:00 — 2 Sept, 21:00

Post Share

Sources

Showing 1 of 1 sources

taiwan-newsMostly Factual1d ago

Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC - Taiwan News

Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC Taiwan News

Read full article →

Ivonescimab Shows Statistically Significant Survival Benefit in Phase III HARMONi-2 Trial for NSCLC

Sources

Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC - Taiwan News

Related Stories

Pentagon Temporarily Rescinds Testosterone Screening Guidance for Troops

RFK Jr. Allegedly Requested Removal of Measles Deaths From CDC Tally

Experts Warn Obsessive Sleep Tracking May Disrupt Rest Quality

UNICEF Reports 20 Million Children Face Annual Online Sexual Abuse